Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Voyager Therapeutics (DE:VT6)
FRANKFURT:VT6
Voyager Therapeutics (VT6) Stock Price & Analysis
3 Followers
VT6 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€5.60 - €13.20
Previous Close€7.35
Volume0.00
Average Volume (3M)396.00
Market Cap
€426.21M
Enterprise Value€213.53M
Total Cash (Recent Filing)$230.88M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)N/A
Beta0.60
Next Earnings
Aug 01, 2024EPS Estimate
-€0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding54,393,628
10 Day Avg. Volume6
30 Day Avg. Volume396
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.95
Price to Sales (P/S)4.44
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.85
Enterprise Value/Gross Profit0.85
Enterprise Value/Ebitda1.14
Forecast
1Y Price Target
€16.22Price Target Upside101.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Voyager Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
3.78% Other Institutional Investors
96.22% Public Companies and
Individual Investors
VT6 FAQ
What was Voyager Therapeutics’s price range in the past 12 months?
Voyager Therapeutics lowest stock price was €5.60 and its highest was €13.20 in the past 12 months.
What is Voyager Therapeutics’s market cap?
Currently, no data Available
When is Voyager Therapeutics’s upcoming earnings report date?
Voyager Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 78 days.
How were Voyager Therapeutics’s earnings last quarter?
Voyager Therapeutics released its earnings results on May 13, 2024. The company reported -€0.185 earnings per share for the quarter, beating the consensus estimate of -€0.407 by €0.222.
Is Voyager Therapeutics overvalued?
According to Wall Street analysts Voyager Therapeutics’s price is currently Undervalued.
Does Voyager Therapeutics pay dividends?
Voyager Therapeutics does not currently pay dividends.
What is Voyager Therapeutics’s EPS estimate?
Voyager Therapeutics’s EPS estimate is -€0.38.
How many shares outstanding does Voyager Therapeutics have?
Currently, no data Available
What happened to Voyager Therapeutics’s price movement after its last earnings report?
Voyager Therapeutics reported an EPS of -€0.185 in its last earnings report, beating expectations of -€0.407. Following the earnings report the stock price went up 9.796%.
Which hedge fund is a major shareholder of Voyager Therapeutics?
Among the largest hedge funds holding Voyager Therapeutics’s share is Farallon Capital Management, L.L.C.. It holds Voyager Therapeutics’s shares valued at 11M.
---
Voyager Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€16.22 (101.03% Upside)
€16.22 (101.03% Upside)
Blogger Sentiment
Bullish
DE:VT6 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $317.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.77%
12-Months-Change
Fundamentals
Return on Equity
89.61%
Trailing 12-Months
Asset Growth
120.44%
Trailing 12-Months
Company Description
Voyager Therapeutics
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
---
VT6 Earnings Call
Q1 2024
0:00 / 0:00
---
VT6 Stock 12 Month Forecast
Average Price Target
€16.22
▲(101.03% Upside)
Technical Analysis
Voyager Therapeutics
―
RegenXBio
―
Ultragenyx Pharmaceutical
―
Crispr Therapeutics AG
―
uniQure
―
Best Analysts Covering VT6
1 Year
1 Year Success Rate
10/15 ratings generated profit
1 Year Average Return
+15.91%
reiterated a buy rating 3 months ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +15.91% per trade.
---